| Birendra Prasad Sah, MD | |
|
90 Presidential Plz, Firm C, Syracuse, NY 13202-2240 | |
| (315) 464-3835 | |
| (315) 464-3837 |
| Full Name | Birendra Prasad Sah |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 22 Years |
| Location | 90 Presidential Plz, Syracuse, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417111287 | NPI | - | NPPES |
| 03347904 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 269316 (New York) | Primary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | 269316 (New York) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Hospital S U N Y Health Science Center | Syracuse, NY | Hospital |
| Auburn Community Hospital | Auburn, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Auburn Community Hospital | 2365346525 | 46 |
| Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In | 3274445796 | 242 |
| Auburn Memorial Medical Services Pc | 6406931385 | 100 |
News Archive
Researchers at Princeton have developed a dual catalyst system that directly installs alkyl groups-fragments containing singly bonded carbon and hydrogen atoms that have extremely useful properties for drug discovery-onto compounds called heteroarenes. The new reaction uses simple and abundant alcohols and offers a milder and more widely applicable alternative to existing strategies.
Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This
A new study conducted by Boston University School of Medicine (BUSM) researchers shows that a majority of medical students in Yemen believe that chewing the plant khat is harmful to one's health but they would not advise their patients to quit.
Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, today announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).
› Verified 3 days ago
| Entity Name | Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063468239 PECOS PAC ID: 3274445796 Enrollment ID: O20031104000051 |
News Archive
Researchers at Princeton have developed a dual catalyst system that directly installs alkyl groups-fragments containing singly bonded carbon and hydrogen atoms that have extremely useful properties for drug discovery-onto compounds called heteroarenes. The new reaction uses simple and abundant alcohols and offers a milder and more widely applicable alternative to existing strategies.
Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This
A new study conducted by Boston University School of Medicine (BUSM) researchers shows that a majority of medical students in Yemen believe that chewing the plant khat is harmful to one's health but they would not advise their patients to quit.
Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, today announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).
› Verified 3 days ago
| Entity Name | Auburn Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093712911 PECOS PAC ID: 2365346525 Enrollment ID: O20031120000617 |
News Archive
Researchers at Princeton have developed a dual catalyst system that directly installs alkyl groups-fragments containing singly bonded carbon and hydrogen atoms that have extremely useful properties for drug discovery-onto compounds called heteroarenes. The new reaction uses simple and abundant alcohols and offers a milder and more widely applicable alternative to existing strategies.
Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This
A new study conducted by Boston University School of Medicine (BUSM) researchers shows that a majority of medical students in Yemen believe that chewing the plant khat is harmful to one's health but they would not advise their patients to quit.
Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, today announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).
› Verified 3 days ago
| Entity Name | Chenango Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770593956 PECOS PAC ID: 7517853633 Enrollment ID: O20040225000911 |
News Archive
Researchers at Princeton have developed a dual catalyst system that directly installs alkyl groups-fragments containing singly bonded carbon and hydrogen atoms that have extremely useful properties for drug discovery-onto compounds called heteroarenes. The new reaction uses simple and abundant alcohols and offers a milder and more widely applicable alternative to existing strategies.
Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This
A new study conducted by Boston University School of Medicine (BUSM) researchers shows that a majority of medical students in Yemen believe that chewing the plant khat is harmful to one's health but they would not advise their patients to quit.
Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, today announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).
› Verified 3 days ago
| Entity Name | Upstate Community Medical, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689620163 PECOS PAC ID: 0143238782 Enrollment ID: O20060323000644 |
News Archive
Researchers at Princeton have developed a dual catalyst system that directly installs alkyl groups-fragments containing singly bonded carbon and hydrogen atoms that have extremely useful properties for drug discovery-onto compounds called heteroarenes. The new reaction uses simple and abundant alcohols and offers a milder and more widely applicable alternative to existing strategies.
Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This
A new study conducted by Boston University School of Medicine (BUSM) researchers shows that a majority of medical students in Yemen believe that chewing the plant khat is harmful to one's health but they would not advise their patients to quit.
Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, today announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).
› Verified 3 days ago
| Entity Name | Auburn Memorial Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194913749 PECOS PAC ID: 6406931385 Enrollment ID: O20080318000053 |
News Archive
Researchers at Princeton have developed a dual catalyst system that directly installs alkyl groups-fragments containing singly bonded carbon and hydrogen atoms that have extremely useful properties for drug discovery-onto compounds called heteroarenes. The new reaction uses simple and abundant alcohols and offers a milder and more widely applicable alternative to existing strategies.
Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This
A new study conducted by Boston University School of Medicine (BUSM) researchers shows that a majority of medical students in Yemen believe that chewing the plant khat is harmful to one's health but they would not advise their patients to quit.
Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, today announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Birendra Prasad Sah, MD 90 Presidential Plz, Firm C, Syracuse, NY 13202-2240 Ph: (315) 464-3835 | Birendra Prasad Sah, MD 90 Presidential Plz, Firm C, Syracuse, NY 13202-2240 Ph: (315) 464-3835 |
News Archive
Researchers at Princeton have developed a dual catalyst system that directly installs alkyl groups-fragments containing singly bonded carbon and hydrogen atoms that have extremely useful properties for drug discovery-onto compounds called heteroarenes. The new reaction uses simple and abundant alcohols and offers a milder and more widely applicable alternative to existing strategies.
Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This
A new study conducted by Boston University School of Medicine (BUSM) researchers shows that a majority of medical students in Yemen believe that chewing the plant khat is harmful to one's health but they would not advise their patients to quit.
Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, today announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).
› Verified 3 days ago
Courtney Myers, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 750 E Adams St Ste 311, Syracuse, NY 13210 Phone: 315-464-5815 | |
Joan Marie Mitchell, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-425-4828 Fax: 315-425-4827 | |
Gordana Obradovic, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1304 Buckley Rd, Suite 200, Syracuse, NY 13212 Phone: 315-478-3311 Fax: 315-476-5211 | |
Kristin A Ramella, NP Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 90 Presidential Plz Ste 5010, Syracuse, NY 13202 Phone: 315-464-9335 | |
Vinodhini M Subramanian, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-470-7111 | |
Robert R. Michiel, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 90 Presidential Plz, 5th Floor, Syracuse, NY 13202 Phone: 315-464-9335 Fax: 315-464-9338 | |
Michael P Gabris, MD FACC Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 E Genesee St, Suite 300, Syracuse, NY 13210 Phone: 315-471-1044 Fax: 315-474-4312 |